Mycoplasma Testing Market Size Worth $4.3 Billion By 2034,CAGR: 13.50%
The global mycoplasma testing market size is expected to reach USD 4.3 Billion by 2034, according to a new study by Polaris Market Research. The report “Mycoplasma Testing Market Share, Size, Trends, Industry Analysis Report, By Product & Service (Assays, Kits, & Reagents, Instruments, Services); By Technique; By Application; By End User; By Region; Segment Forecast, 2025 - 2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.
Mycoplasma is a type of bacteria without a cell wall. It is mostly likely to affect the respiratory, urinary, and genital tracts of humans. The presence of stringent regulations and growing concerns about consumer safety is enabling pharmaceutical companies to focus on comprehensive biological testing, including testing of mycoplasma.
A 2023 study published in the Journal of Microbiology focused on exploring advancements in the detection of Mycoplasma genitalium. The recent clearance of molecular-based assays by the U.S. Food and Drug Administration (FDA) permitted diagnostic testing to be widely employed in the United States, making it no longer available only in some laboratories. This is positively influencing the growth of the mycoplasma market.
The emergence of antimicrobial resistance made it difficult to test the presence of mycoplasma in pharmaceutical products and services, which fueled the development of diagnostic tests to determine resistance. Mycoplasma is mostly found in the production phase of biopharmaceutical products, including from the research stage to clinical development, highlighting the need for mycoplasma testing to check safety and accuracy in treating certain diseases.
The growing research innovations in this field and the adoption of advanced technologies are anticipated to promote the expansion of the mycoplasma testing market. For instance, in November 2023, QIAGEN unveiled its three new QIAcuity kits and software update to expand its product line for polymerase chain reaction technology in cell and gene therapies, the food industry, and the pharmaceutical industry.
Ongoing expansion activities by biopharmaceutical companies to enhance the quality and safety of their products are positively influencing the mycoplasma testing market. For instance, in November 2023, Bionique, a pharmaceutical lab specializing in protecting medicines from bacteria, expanded its location at Lake Clear, New York, to meet ongoing demand from rapidly growing cell and gene therapies in the region.
Mycoplasma Testing Market Report Highlights
- Assays, Kits, & reagents segment is anticipated to witness the highest growth in the coming years due to the need for ready-to-test kits.
- NAT segment accounted for the largest market share owing to its capability to offer faster results.
- Cell line testing segment is projected to experience a larger revenue share due to growing biopharmaceutical production.
- Asia Pacific is projected to register the fastest growth during the forecast period, attributable to the rising innovations in cell and gene therapies.
- The global players include Agilent Technologies, American Type Culture Collection, Biological Industries Israel Beit Haemek Ltd, & Bionique Testing Laboratories, Inc.
Request a free sample copy or read the full market insights : mycoplasma testing market Report
Polaris Market Research has segmented the mycoplasma testing market report based on product & service, technique, application, end user and region:
Mycoplasma Testing, Product & Service Outlook (Revenue - USD Billion, 2020 - 2034)
- Assays, Kits, & Reagents
- NAT assays, kits, & reagents
- ELISA assays, kits, & reagents
- Elimination Kits
- Stains
- Other assays, kits, & reagents
- Instruments
- Services
Mycoplasma Testing, Technique Outlook (Revenue - USD Billion, 2020 - 2034)
- NAT
- ELISA
- Staining
- Other technique
Mycoplasma Testing, Application Outlook (Revenue - USD Billion, 2020 - 2034)
- Cell line testing
- Virus Testing
- End-of-Production cell testing
Mycoplasma Testing, End User Outlook (Revenue - USD Billion, 2020 - 2034)
- Pharmaceutical & Biotechnology Companies
- Cell Banks & Laboratories
- Contract Research Organizations
- Academic Research Institutes
Mycoplasma Testing, Regional Outlook (Revenue - USD Billion, 2020 - 2034)
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Netherlands
- Asia Pacific
- China
- India
- Japan
- South Korea
- Indonesia
- Malaysia
- Latin America
- Argentina
- Brazil
- Mexico
- Middle East & Africa
- UAE
- Saudi Arabia
- Israel
- South Africa
Mycoplasma Testing Market Report Scope
| Report Attributes | Details |
| Market size value in 2025 | USD 1.36 Billion |
| Revenue forecast in 2034 | USD 4.3 Billion |
| CAGR | 13.50% from 2025 – 2034 |
| Base year | 2024 |
| Historical data | 2020 – 2023 |
| Forecast period | 2025 – 2034 |
| Quantitative units | Revenue in USD Billion and CAGR from 2025 to 2034 |
| Segments covered |
|
| Regional scope |
|
| Competitive Landscape |
|
| Report Format |
|
| Customization | Report customization as per your requirements with respect to countries, region and segmentation. |
| For Specific Research Requirements |
